Posted by Michael Wonder on 02 Mar 2020
FDA approves new therapy for patients with previously treated multiple myeloma
2 March 2020 - Today, the U.S. FDA approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Sarclisa, administered through intravenous infusion, is a CD38-directed cytolytic antibody that works by helping certain cells in the immune system attack multiple myeloma cancer cells.
The FDA approved Sarclisa based on the results of a clinical trial involving 307 patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
